Disc Medicine, Inc.
IRON
Positions held
Your positionsIRON isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Disc Medicine, Inc. operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, offering significant growth opportunities for investors.
- The company's market capitalization stands at approximately $2.37 billion, indicating a substantial valuation in the biotechnology space.
- Disc Medicine has a target mean price of $103.17, suggesting a potential upside from current levels.
- Disc Medicine, Inc. has reported negative net income consistently, with a net loss of $59.53 million in Q2 2026, highlighting ongoing financial challenges.
- The company has a profit margin of 0.0%, indicating that it is currently not generating profits.
- Disc Medicine has a strong sell signal with a score of -24.00, reflecting negative trends and bearish market indicators.
Fundamentals
| Market cap | $2.33B | Enterprise value | $1.68B | Trailing P/E | — | Forward P/E | -8.58 |
| PEG | — | Price / book | 3.62 | Beta | 2.11 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -39.1% | ROA | -24.0% | Debt / equity | 0.09 |
| Current ratio | 24.14 | Free cash flow | -$117.54M | Analyst recommendation | strong_buy | Mean target | $103.17 |
| 52w high | $99.50 | 52w low | $40.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$59.5M | -$63.5M | -$60.5M | -$62.3M | -$55.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$65.1M | -$69.5M | -$67.0M | -$67.7M | -$61.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$212M | -$109M | -$76.4M | -$46.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$236M | -$130M | -$91.1M | -$47.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-02 · Disc Medicine to Participate in Upcoming Investor Conferences
2026-09-02 · Wedbush Raises Price Target on Disc Medicine to $100 From $88, Keeps Outperform Rating
2026-08-17 · Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
2026-08-17 · Morgan Stanley Adjusts Price Target on Disc Medicine to $90 From $85, Keeps Overweight Rating
2026-08-07 · Disc Medicine Insider Sold Shares Worth $400,000, According to a Recent SEC Filing
2026-07-30 · Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-15 · Disc Medicine Insider Sold Shares Worth $2,473,780, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns